Patents Represented by Attorney Kenton Abel
-
Patent number: 8273358Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: August 15, 2008Date of Patent: September 25, 2012Assignee: Allergan, Inc.Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
-
Patent number: 8273865Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions may be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.Type: GrantFiled: September 16, 2010Date of Patent: September 25, 2012Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
-
Patent number: 8257914Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.Type: GrantFiled: August 21, 2009Date of Patent: September 4, 2012Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
-
Patent number: 8236513Abstract: The present invention provides BoNT/A peptide compositions, tolerogizing compositions, BoNT/A immune response inducing compositions and antibody compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of preventing or reducing immunoresistance to botulinum toxin therapy in an individual, methods of vaccinating an individual against botulinum toxin, methods of preparing anti-BoNT/A antibodies, methods of treating botulinum toxicity in an individual and methods of reducing anti-botulinum toxin antibodies in an individual.Type: GrantFiled: August 15, 2008Date of Patent: August 7, 2012Assignee: Baylor College of MedicineInventor: M. Zouhair Atassi
-
Patent number: 8211671Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: July 22, 2008Date of Patent: July 3, 2012Assignee: Allergan, Inc.Inventors: J. Oliver Dolly, Yan Li, Kuo Chion Chan
-
Patent number: 8206723Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: GrantFiled: April 1, 2009Date of Patent: June 26, 2012Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 8198034Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.Type: GrantFiled: March 13, 2009Date of Patent: June 12, 2012Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Roger Aoki
-
Patent number: 8198229Abstract: The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.Type: GrantFiled: May 17, 2010Date of Patent: June 12, 2012Assignee: Allergan, Inc.Inventors: Joseph Francis, Dean G. Stathakis
-
Patent number: 8137675Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: October 29, 2009Date of Patent: March 20, 2012Assignees: Allergan, Inc., Baylor College of MedicineInventor: M. Zouhair Atassi
-
Patent number: 8128940Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.Type: GrantFiled: March 14, 2006Date of Patent: March 6, 2012Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei R. Aoki
-
Patent number: 8124357Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.Type: GrantFiled: April 4, 2006Date of Patent: February 28, 2012Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
-
Patent number: 8119767Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.Type: GrantFiled: January 17, 2007Date of Patent: February 21, 2012Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
-
Patent number: 8119370Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: August 22, 2008Date of Patent: February 21, 2012Assignee: Allergan, Inc.Inventors: J. Oliver Dolly, Yan Li, Kuo Chion Chan
-
Patent number: 8071110Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: August 15, 2008Date of Patent: December 6, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
-
Patent number: 8067231Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that contains an exogenous Clostridial toxin substrate which comprises a fluorescent member, a membrane targeting domain and a Clostridial toxin recognition sequence comprising a cleavage site, where the cleavage site intervenes between the fluorescent member and the membrane targeting domain; and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.Type: GrantFiled: April 4, 2006Date of Patent: November 29, 2011Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
-
Patent number: 8053209Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.Type: GrantFiled: November 17, 2009Date of Patent: November 8, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
-
Patent number: 8052979Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.Type: GrantFiled: March 14, 2006Date of Patent: November 8, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
-
Patent number: 8053208Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.Type: GrantFiled: November 17, 2009Date of Patent: November 8, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
-
Patent number: 8048643Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.Type: GrantFiled: November 17, 2009Date of Patent: November 1, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
-
Patent number: 8022172Abstract: Clostridial toxin substrates comprising a lanthanide donor complex, an acceptor, and a Clostridial toxin recognition sequence including a cleavage site; methods for determining the activity of a Clostridial toxin from a test sample using such Clostridial toxin substrates; cell compositions comprising such Clostridial toxin substrates and a Clostridial toxin receptor; and methods for determining the activity of a Clostridial toxin from a test sample using such cell compositions.Type: GrantFiled: May 23, 2007Date of Patent: September 20, 2011Assignee: Allergan, Inc.Inventors: Dudley J. Williams, Marcella A. Gilmore, Lance E. Steward, Marc Verhagen, Kei Roger Aoki, Ester Fernandez-Salas